SLAM Bio is a preclinical stage biotech company developing a platform of antibodies and antibody drug conjugates (ADCs) against signaling lymphocytic activation molecule (SLAM) protein family. SLAM's lead program is a first-in-class humanized antibody and ADC targeting CD84 (SLAMF5), a cell surface adhesion molecule that is expressed on immune cells and acts as a master regulator of the immune response. In oncology applications, we have preclinical proof of concept in AML, breast cancer, myeloma and CLL. We are developing an antibody drug conjugate (ADC) that can be applied on select antibodies in our portfolio.